Aleglitazar is a PPAR-α/γ agonist which shows improvements in non-invasive tests assessing hepatic steatosis and fibrosis, further supporting the utility of the PPAR pathway in managing NAFLD [218]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.